Regulatory News:
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announces today its corporate agenda* for 2012:
| 2 February 2012: | Full year 2011 sales | |
| 29 February 2012: | Full year 2011 results | |
| 3 May 2012: | First quarter 2012 sales | |
| 1 June 2012: | General shareholders´ meeting | |
| 11 June 2012: | Payment of 2011 dividend** | |
| 28 August 2012: | First half 2012 sales & results | |
| 29 October 2012: | First nine months 2012 sales |
* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary.
** Pending approval of the Board of directors (28th February 2012) and of the General shareholders´ meeting (1st June 2012)
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2010. Ipsen´s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,500 employees. Ipsen´s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
